Adverse events grade 3 to 5 Range of · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade III–V adverse events compared with saline (low certainty).
1 finding from 1 review
Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes time to death from bladder cancer(absolute effect size estimates… compared with saline (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes time to death from any cause (absolute effect size estimates based… compared with saline (very low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade I or II adverse events compared with saline (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence · patients with non‐muscle invasive bladder cancer
Gemcitabine may leads to lower time to recurrence compared with mitomycin (low certainty).
1 finding from 1 review
Time to progression · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in time to progression compared with mitomycin (low certainty).
1 finding from 1 review
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Helath‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes grade 1 ‐ 4 anaemia compared with S‐1 (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review